Drugs / TGF-betaR2KO/IL13R-alpha2-CAR T cells
TGF-betaR2KO/IL13R-alpha2-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06815029 | Jun 2025 → Oct 2030 expected | astrocytoma, IDH-mutant, grade 3, astrocytoma, IDH-mutant, grade 4, glioblastoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGF-betaR2KO/IL13R-alpha2-CAR T cells | “Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially” NCT06815029 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells.” NCT06815029 ↗ |
| Route | Other | “intracranially” NCT06815029 ↗ |